Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency

Drugs of Today

Volumn 49, Issue 3, 2013, Pages 161-170

  Haddley, Kate ^a  

^a Freelance Writer   (United Kingdom)

Author keywords

AaV1 LpLS447X; Alipogene tiparvovec; AMT 010; AMT 011; Baculovirus; Lipoprotein lipase deficiency

Indexed keywords

ALIPOGENE TIPARVOVEC; APOLIPOPROTEIN E; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DYSLIPIDEMIA; EMBRYOTOXICITY; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; HYPERTRIGLYCERIDEMIA; INJECTION SITE REACTION; LOW DRUG DOSE; LYMPHOID HYPERPLASIA; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE INJURY; MYOSITIS; NONHUMAN; OPEN READING FRAME; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CLEARANCE; TISSUE DISTRIBUTION; WEIGHT REDUCTION;

AAV1-LPL(S447X); ALIPOGENE TIPARVOVEC; AMT-010; AMT-011; BACULOVIRUS; LIPOPROTEIN LIPASE DEFICIENCY;

ANIMALS; CLINICAL TRIALS AS TOPIC; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; HUMANS; HYPERLIPOPROTEINEMIA TYPE I; LIPOPROTEIN LIPASE; MUTATION; TRIGLYCERIDES;

EID: 84875745954     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.3.1937398     Document Type: Article

References (57)

1. Brunzell, J. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: The Metabolic and Molecular of Inherited Disease, 7th Ed. Scriver, C., Baudet, a., Sly, W., Valle, D. (Eds.). Mcgraw-hill: new York 1995, 1913-32.
2. Ylae-herttuala, S. Endgame: Glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther 2012, 20(10): 1831.
3. gagne, C, Brun, L.D., Julien, p., Moorjani, S., Lupien, p.J. Primary lipoprotein-lipase-activity deficiency: Clinical investigation of a French-Canadian population. CMaJ 1989, 140(4):405-11.
4. goldberg, I.J., Merkel, M. Lipoprotein lipase: Physiology, biochemistry, and molecular biology. Front Biosci 2001, 6: D388-405.
5. ross, C.J.D., Twisk, J., Meulenberg, J.M. et al. Long-term correction of murine lipoprotein lipase deficiency with AAV1- mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation. hum gene Ther 2004, 15(9): 906-19.
6. rip, J., nierman, M.C., Sierts, J.a. et al. Gene therapy for lipoprotein lipase deficiency: Working toward clinical application. hum gene Ther 2005, 16(11): 1276-86.
7. rip, J., nierman, M.C., Sierts, J.a. et al. Gene therapy for genetic lipoprotein lipase (LPL) deficiency; an update. 8th annu Meet am Soc gene Ther (aSgT) (June 1-5, St. Louis) 2005, abst 907.
8. rahalkar, a.r., giffen, F., har, B. et al. Novel LPL mutations associated with lipoprotein lipase deficiency: Two case reports and a literature review. Can J physiol pharmacol 2009, 87(3): 151-60.
9. rip, J., nierman, M.C., ross, C.J., Jukema, J.W. et al. Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation. arterioscler Thromb Vasc Biol 2006, 26(6): 1236-45.
10. anganathan, g., Unal, r., pokrovskaya, I.D. et al. The lipoprotein lipase (LPL) S447X gain of function variant involves increased mRNA translation. atherosclerosis 2012, 221(1): 143-7.
11. nierman, M.C., rip, J., Twisk, J. et al. Gene therapy for genetic lipoprotein lipase deficiency: from promise to practice. neth J Med 2005, 63(1): 14-9.
12. Brunzell J., Deeb, S. Familial lipoprotein lipase deficiency, ApoCII deficiency, and hepatic lipase deficiency. In: The Metabolic and Molecular Bases of Inherited Disease. C. Scriver, a. Beaudet, W. Sly, D. Valle (Eds.) Mcgraw-hill Inc: new York 2001, 2789-816.
13. petry, h., gaudet, D., Carpentier, a. et al. Alipogene tiparvovec: The first gene therapy for a general metabolic disorder. hum gene Ther 2010, 21(9): abst Inv 15.
14. gaudet, D., de Wal, J., Tremblay, K. et al. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. atheroscler Suppl 2010, 11: 55-60.
15. gasbarrini, g., Mingrone, g., greco, a.V., Castagneto, M. An 18-year-old woman with familial chylomicronaemia who would not stick to a diet. Lancet 1996, 348(9030): 794.
16. AMT receives Orphan Drug designation from FDA for AMT- 011 for the treatment of lipoprotein lipase deficiency [news release]. amsterdam Molecular Therapeutics BV, June 4, 2007.
17. nierman, M.C., Stroes, E.S., Twisk, J. et al. A gene therapy approach to treat human lipoprotein lipase deficiency. atherosclerosis Suppl 2006, 7(3): abst Mo-W5:2.
18. arruda, V.r., Schuettrumpf, J., herzog, r.W. et al. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood 2004, 103(1): 85-92.
19. Wittrup, h.h., nordestgaard, B.g., Steffensen, r., Jensen, g., Tybjaerg-hansen, a. Effect of gender on phenotypic expression of the S447X mutation in LPL: The Copenhagen City Heart Study. atherosclerosis 2002, 165(1): 119-26.
20. Twisk, J., ross, C.J.D., Kuivenhoven, J.a. et al. Long-term correction of murine lipoprotein lipase deficiency by single intramuscular administration of AAV1-LPL(S447X). 11th annu Congr Eur Soc gene Ther (ESgT) (november 14-17, Edinburgh) 2003, abst p240.
21. grimm, D., Kay, M.a., Kleinschmidt, J.a. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther 2003, 7(6): 839-50.
22. Twisk, J., ross, C.J.D., Comijn, L. et al. Evaluation of recombinant AAV1 produced in insect cells for muscle-directed gene transfer. 15th annu Congr Eur Soc gene Cell Ther (ESgCT) (october 27-30, rotterdam) 2007, abst p180.
23. ross, C.J.D., Twisk, J., Kuivenhoven, J.a. et al. Correction of dyslipidemia in murine and feline models of lipoprotein lipase deficiency by intramuscular administration of AAV1- LPLS447X. 7th annu Meet am Soc gene Ther (aSgT) (June 2-6, Minneapolis) 2004, abst 40.
24. rip, J., van Dijk, K.W., Sierts, J.a. et al. AAV1-LPLS447X gene therapy reduces hypertriglyceridemia in apoE2 knock in mice. Biochim Biophys acta - Mol Cell Biol Lipids 2006, 1761(10): 1163-8.
25. rip, J., Sierts, J.a., Vaessen, S.F. et al. Adeno-associated virus LPL(S447X) gene therapy in LDL receptor knockout mice. atherosclerosis 2007, 194(1): 55-61.
26. Kaeppel, C., Beattie, S., nowrouzi, a. et al. Absence of integration hotspots in mice after intramuscular injection of AAV1-LPLS447X. 14th annu Meet am Soc gene Ther (aSgT) (May 18-21, Seattle) 2011, abst 123.
27. ross, C.J.D., Twisk, J., Kuivenhoven, J. et al. Correction of hypertriglyceridemia in lipoprotein lipase deficient cats by intramuscular administration of AAV1-LPLS447X. 54th annu Meet am Soc hum genet (aShg) (october 26-30, Toronto) 2004, abst 274.
28. ross, C.J.D., Twisk, J., Bakker, a.C. et al. Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. hum gene Ther 2006, 17(5): 487-99.
29. ross, C., Twisk, J., rip, J. et al. AAV1-mediated gene therapy for LPL deficiency. 55th annu Meet am Soc hum genet (aShg) (october 25-29, Salt Lake City) 2005, abst 201.
30. ross, C.J., Twisk, J., rip, J. et al. From genes to therapies: AAV-mediated gene therapy for LPL deficiency. Circulation 2005, 112(17, Suppl. 2): abst 693.
31. rip, J., nierman, M.C., Sierts, J.a. et al. Working towards clinical application of gene therapy for LPL deficiency. Circulation 2003, 108(17, Suppl. 4): abst 628.
32. nierman, M., Twisk, J., hermens, J et al. Safety and efficacy of AMT-010, an adeno-associated virus-based gene therapy vector administered to lipoprotein lipase-deficient subjects. 15th annu Congr Eur Soc gene Cell Ther (ESgCT) (october 27-30, rotterdam) 2007, abst Inv 3.
33. Van amersfoort, E., Waalkens-Berendsen, I., Bauer, U., Meulenberg, J., Twisk, J. Treatment of female mice with AAV1-LPLS447X at 4 weeks prior to mating has no effect on reproductive potential and does not result in embryotoxicity or germ line transmission. 15th annu Congr Eur Soc gene Cell Ther (ESgCT) (october 27-30, rotterdam) 2007, abst or 51.
34. Van amersfoort, E.S., Waalkens-Berendsen, I.h., Bauer, U. et al. Treatment of female mice with AMT-011 (AAV1- LPLS447X) at 4 weeks prior to mating has no effect on reproductive potential and does not result in embryotoxicity of germ line transmission. 11th annu Meet am Soc gene Ther (aSgT) (May 28-June 1, Boston) 2008, abst 791.
35. Freidig, a., Salmon, F., Jenal, U., petry, h. Use of non-clinical and clinical data for the environmental risk assessment of Glybera (alipogene tiparvovec). hum gene Ther 2010, 21(10): abst p 14.
36. nierman, M.C., Twisk, J., hermens, W.T. et al. Biodistribution of AAV1-LPL-S447X vector sequences after intramuscular administration to lipoprotein lipase deficient patients. 10th annu Meet am Soc gene Ther (aSgT) (May 30-June 3, Seattle) 2007, abst 348.
37. nierman, M., Twisk, J., hermens, W. et al. Biodistribution of AAV1-LPLS447X (AMT-010) vector sequences after intramuscular administration to lipoprotein lipase-deficient patients. 15th annu Congr Eur Soc gene Cell Ther (ESgCT) (october 27-30, rotterdam) 2007, abst or 50.
38. gaudet, D., Methot, J., Essiembre, C. et al. Biodistribution of AAV1-LPL S447X vector co-administered with immunosuppression to lipoprotein lipase deficient patients in a phase II study. 11th annu Meet am Soc gene Ther (aSgT) (May 28- June 1, Boston) 2008, abst 985.
39. Stroes, E., Kuivenhoven, J., van Deventer, S., Kastelein, J. Safety and efficacy of AMT-010 gene therapy in lipoprotein lipase deficiency (LPLD). atherosclerosis Suppl 2009, 10(2): p475.
40. Stroes, E.S., nierman, M.C., Meulenberg, J.J. et al. Intra - muscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. arterioscler Thromb Vasc Biol 2008, 28(12): 2303-4.
41. Gene transfer safety symposium: Immune responses to adeno-associated virus vectors. Session II: Immune responses in clinical studies using AAV vectors. Immune responses in a lipoprotein lipase deficiency study using AAV-1-LPLS447X. office of Biotechnology activities, office of the Director, nIh US DEparTMEnT hEaLTh hUM SErVICES 2007 June 19: 4-5.
42. AMT presents positive results of phase I/II study with lead product at annual meeting of American Society of Gene Therapy [news release]. amsterdam Molecular Therapeutics BV, May 31, 2007.
43. A study to determine the safety and efficacy in lipoprotein lipase-deficient subjects after intramuscular administration of AMT-011, an adeno-associated viral vector expressing human lipoprotein lipase S447X (NCT01109498). ClinicalTrials.gov Web site. accessed January 10, 2013.
44. AMT announces positive interim clinical data on its lead product AMT-011 [news release]. amsterdam Molecular Therapeutics BV, May 30, 2008.
45. gaudet, D., Brisson, D., Methot, J., van Deventer, S. An open label, dose escalation study to assess the safety and efficacy of AAV1-LPL gene therapy with alipogene tiparvovec (AMT- 011) for patients with severe hypertriglyceridemia due to lipoprotein lipase deficiency (LPLD). atherosclerosis Suppl 2009, 10(2): abst 554.
46. An open-label study to assess the efficacy and safety of alipogene tiparvovec (AMT-011), human LPL [S447X], expressed by an adeno-associated viral vector after intramuscular administration in LPL-deficient adult subjects (NCT00891306). ClinicalTrials.gov Web site. accessed January 10, 2013.
47. Twisk, J., Frisch, F., greentree, S. et al. Improved chylomicron clearance as a marker for long-term efficacy of alipogene tiparvovec (AAV1-LPLS447X gene therapy) in LPLD patients. 14th annu Meet am Soc gene Ther (aSgT) (May 18-21, Seattle) 2011, abst 183.
48. Twisk, J., Frisch, F., Ferreira, V. et al. Long-term transgene expression and biological effect following IM administration of AAV1-LPLS447X to LPL deficient patients. 15th annu Meet am Soc gen Cell Ther (aSgCT) (May 16-19, philadelphia) 2012, abst 55.
49. Carpentier, a.C., Frisch, F., Labbe, S.M. et al. Effect of alipogene tiparvovec (AAV1-LPLS447X) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab 2012, 97(5): 1635-44.
50. Prospective, non-interventional, non-randomised, openlabel, adult study to assess the long term biological therapeutic response to alipogene tiparvovec in lipoprotein lipase deficiency (LPLD) and comparing postprandial chylomicron metabolism following a radiolabeled meal in LPLD subjects previously treated with alipogene tiparvovec (Studies CTAMT- 011-01 or -02) to untreated LPLD subjects (Study PREPARATION-02) and to healthy volunteers (NCT01447901). ClinicalTrials.gov Web site. accessed January 10, 2013.
51. A clinical records review study of the frequency and severity of acute abdominal "pancreatitis" episodes reported from LPLD subjects previously recruited to clinical studies PREPARATION- 02, CT-AMT-011-01 and CT-AMT-011-02 (NCT01448577). ClinicalTrials.gov Web site. accessed January 10, 2013.
52. Bruno, M.J., Deakin, M., Ruszniewski, P.B. et al. Alipogene tiparvovec gene therapy reduces the risk of acute pancreatitis in patients with lipoprotein lipase deficiency. Dig Dis Week (May 19-22, San Diego) 2012, abst 557.
53. Franssen, R., Gaudet, D., Stroes, E.S. et al. AAV1-LPLS447X gene therapy with alipogene tiparvovec prevents pancreatitis in lipoprotein lipase deficiency. Circulation 2009, 120(18, Suppl. 2): abst 2093.
54. de Wal, J., Dery, S., Gagne, C. et al. Alipogene tiparvovec (AAV1-LPLS447X gene therapy) is long-term safe and efficacious in patients with lipoprotein lipase deficiency. annu Symp Soc Study Inborn Errors Metab (SSIEM) (august 30- September 2, geneva) 2011, abst o-057.
55. Mingozzi, F., Meulenberg, J.J., hui, D.J. et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dosedependent activation of capsid-specific T cells. Blood 2009, 114(10): 2077-86.
56. Mingozzi, F., Meulenberg, J., hui, D. et al. Intramuscular administration of an AAV-1 vector in humans results in capsid- specific T cell responses. 10th annu Meet am Soc gene Ther (aSgT) (May 30-June 3, Seattle) 2007, abst 1056.
57. Mingozzi, F., Kleefstra, a., Meulenberg, J. et al. Modulation of T cell response to the AAV capsid in subjects undergoing intramuscular gene transfer for lipoprotein lipase deficiency. hum gene Ther 2008, 19(10): abst or 38.